Kouvaraki MA, Shapiro SE, Fornage BD, Edeiken-Monro BS, Sherman SI, Vassilopoulou-Sellin R et al (2003) Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 134(6):946–954 (discussion 54–5)

Kraeber-Bodere F, Rousseau C, Bodet-Milin C, Ferrer L, Faivre-Chauvet A, Campion L et al (2006) Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med Official Publ Soc Nucl Med 47(2):247–255

Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R et al (2011) Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol Official J Am Soc Clin Oncol 29(19):2660–2666CrossRef

Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J et al (2010) Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol Official J Am Soc Clin Oncol 28(14):2323–2330CrossRef

Laure Giraudet A, Al Ghulzan A, Auperin A, Leboulleux S, Chehboun A, Troalen F et al (2008) Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol Eur Fed Endocr Soc 158(2):239–246

Lindsey SC, Ganly I, Palmer F, Tuttle RM (2015) Response to initial therapy predicts clinical outcomes in medullary thyroid cancer. Thyroid Official J Am Thyroid Assoc 25(2):242–249CrossRef

Lorenz K, Brauckhoff M, Behrmann C, Sekulla C, Ukkat J, Brauckhoff K et al (2005) Selective arterial chemoembolization for hepatic metastases from medullary thyroid carcinoma. Surgery 138(6):986–993 (discussion 93)

Machens A, Dralle H (2010) Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 95(6):2655–2663CrossRefPubMed

Machens A, Dralle H (2013a) Prognostic impact of N staging in 715 medullary thyroid cancer patients: proposal for a revised staging system. Ann Surg 257(2):323–329CrossRefPubMed

Machens A, Dralle H (2013b) Benefit-risk balance of reoperation for persistent medullary thyroid cancer. Ann Surg 257(4):751–757CrossRefPubMed

Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD et al (2003) Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349(16):1517–1525CrossRefPubMed

Machens A, Schneyer U, Holzhausen HJ, Dralle H (2005) Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 90(4):2029–2034CrossRefPubMed

Mahler C, Verhelst J, de Longueville M, Harris A (1990) Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin Endocrinol 33(2):261–269CrossRef

Marsh DJ, Andrew SD, Eng C, Learoyd DL, Capes AG, Pojer R et al (1996a) Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma. Cancer Res 56(6):1241–1243PubMed

Marsh DJ, Learoyd DL, Andrew SD, Krishnan L, Pojer R, Richardson AL et al (1996b) Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol 44(3):249–257CrossRef

Martinez SR, Beal SH, Chen A, Chen SL, Schneider PD (2010) Adjuvant external beam radiation for medullary thyroid carcinoma. J Surg Oncol 102(2):175–178PubMedCentralCrossRefPubMed

Meijer JA, le Cessie S, van den Hout WB, Kievit J, Schoones JW, Romijn JA et al (2010) Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Clin Endocrinol 72(4):534–542CrossRef

Mian C, Pennelli G, Barollo S, Cavedon E, Nacamulli D, Vianello F et al (2011) Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. Eur J Endocrinol Eur Fed Endocr Soc 164(6):971–976CrossRef

Mirallie E, Vuillez JP, Bardet S, Frampas E, Dupas B, Ferrer L et al (2005) High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J clin Endocrinol Metab 90(2):779–788CrossRefPubMed

Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A et al (1998) Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’etude des tumeurs a calcitonine. Clin Endocrinol 48(3):265–273CrossRef

Moley JF, Fialkowski EA (2007) Evidence-based approach to the management of sporadic medullary thyroid carcinoma. World J Surg 31(5):946–956CrossRefPubMed

Moura MM, Cavaco BM, Pinto AE, Domingues R, Santos JR, Cid MO et al (2009) Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer 100(11):1777–1783PubMedCentralCrossRefPubMed